

DR. REDDY'S LABORATORIES LIMITED
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011

All amounts in Indian Rupees lakhs, except share data

Sl. No.	PARTICULARS	Quarter ended		Year ended
		30.06.11	30.06.10	31.03.11
		(Unaudited)	(Unaudited)	(Audited)
1	Sales / Income from operations (including Excise Duty)	168,508	126,399	525,368
	Less: Excise duty	937	777	3,564
	Net sales / income from operations	167,571	125,622	521,804
2	License fees and service income	807	569	3,103
3	Other operating income	1,318	935	5,534
4	Total operating income (1 + 2 + 3)	169,696	127,126	530,441
5	Total expenditure	115,413	101,286	436,682
a	(Increase) / decrease in stock	(3,146)	(3,373)	(7,899)
b	Material consumed	47,804	43,826	181,116
c	Research and development expenses, net	11,911	9,443	51,286
d	Personnel costs	20,363	15,389	70,113
e	Selling expenses	13,928	13,019	47,713
f	Other expenditure	17,660	17,262	63,985
g	Depreciation and amortisation	6,893	5,720	24,794
h	Provision for decline in the value of long-term investments	-	-	5,574
6	Profit from operations before other income, interest and exceptional items (4 - 5)	54,283	25,840	93,759
7	Other income	5,554	2,092	11,960
8	Profit before interest and exceptional items (6 + 7)	59,837	27,932	105,719
9	Interest	1,524	46	538
10	Profit before exceptional items (8 - 9)	58,313	27,886	105,181
11	Exceptional items	-	-	-
12	Profit from ordinary activities before tax (10 - 11)	58,313	27,886	105,181
13	Tax expense	12,908	3,438	15,850
14	Net Profit from ordinary activities after tax (12 - 13)	45,405	24,448	89,331
15	Extra-ordinary items	-	-	-
16	Net profit for the period / year (14 - 15)	45,405	24,448	89,331
17	Paid - up equity share capital (face value Rs.5/- each)	8,474	8,457	8,463
18	Paid up debt capital	-	-	-
18	Reserves (excluding revaluation reserve)			593,537
20	Debenture redemption reserve			
19	Earnings per share for the period (in Rupees) per Rs.5/- share			
	a) Before Extra-ordinary items			
	- Basic	26.82	14.48	52.82
	- Diluted	26.65	14.37	52.51
	b) After Extra-ordinary items			
	- Basic	26.82	14.48	52.82
	- Diluted	26.65	14.37	52.51
	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)
22	a) Debt equity ratio			
	b) Debt service coverage ratio			
	c) Interest service coverage ratio			
20	Public share holding*			
	-Number of shares (Face value Rs.5/- each)	93,828,201	98,897,537	94,124,752
	-Percentage of share holding	55.36	58.47	55.61
21	Promoters and promoter group Shareholding			
a	Pledged/Encumbered			
	- Number of shares	2,100,000	2,100,000	2,100,000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	4.84	4.83	4.84
	- Percentage of shares (as a % of the total share capital of the company)	1.24	1.24	1.24
b	Non-encumbered			
	- Number of shares	41,317,812	41,417,812	41,317,812
	- Percentage of shares (as a % of the total shareholding)	95.16	95.17	95.16

DR. REDDY'S LABORATORIES LIMITED
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011

	of promoter and promoter group			
	- Percentage of shares (as a % of the total share capital of the company)	24.38	24.49	24.41

*Public Share Holding as defined under Clause 40A of Listing Agreement (excludes shares held by Promoters, Promoter Group and American Depository Receipt Holders)

DR. REDDY'S LABORATORIES LIMITED
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2011

Sl. No.	PARTICULARS	Quarter ended		Year ended
		30.06.11	30.06.10	31.03.11
		(Unaudited)	(Unaudited)	(Audited)
1	Segment wise revenue, results and capital employed:			
	Segment revenue :			
	a) Pharmaceutical Services and Active Ingredients	52,900	44,012	205,467
	b) Global Generics	126,833	90,904	356,227
	c) Proprietary Products	36	43	252
	Total	179,769	134,959	561,946
	Less: Inter segment revenue	9,293	7,765	31,551
	Add : Other unallocable Income	4,774	2,024	12,006
	Total income	175,250	129,218	542,401
2	Segment results :			
	Profit / (loss) before tax and interest from each segment			
	a) Pharmaceutical Services and Active Ingredients	3,531	4,847	30,997
	b) Global Generics	59,589	33,255	96,210
	c) Proprietary Products	(2,797)	(2,090)	(11,693)
	Total	60,323	36,012	115,514
	Less: (i) Interest	1,524	46	538
	(ii) Other un-allocable expenditure, net	486	8,080	9,795
	Total profit before tax	58,313	27,886	105,181
3	Capital Employed :			
	a) Pharmaceutical Services and Active Ingredients	181,954	147,358	177,497
	b) Global Generics	311,882	197,565	265,407
	c) Proprietary Products	866	819	303
	d) Unallocated	154,027	266,463	158,793
	Total	648,729	612,205	602,000

Notes:

- 1 Pursuant to clause 41 of the Listing Agreement, the investor complaints received, disposed off and lying unresolved for the quarter ended 30 June 2011 are given in the table below:

Nature of Complaints	Opening balance	Received	Disposal	Closing Balance
Non receipt of shares	1	Nil	1	Nil

- 2 The un-audited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 20 July 2011.
- 3 On 20 June 2011, the Company announced a scheme whereby employees, based on an eligibility criteria, could opt and apply for voluntary retirement (i.e., a termination benefit). As per the scheme, employees whose applications are accepted by the Company will be paid the termination benefit in accordance with the methodology prescribed in the scheme. The termination benefit is however restricted to a maximum of Rs. 8 lakhs per employee. As at 30 June 2011, the Company has estimated and provided a sum of Rs. 1,358 lakhs towards the liability.

By order of the Board
For Dr. Reddy's Laboratories Limited

Place: Hyderabad
Date: 20 July 2011

Satish Reddy
Managing Director & Chief Operating Officer